美国肺动脉高压治疗中断的相关因素。
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States.
作者信息
Farber Harrison W, Germack Hayley D, Croteau Nicole S, Simeone Jason C, Tang Fei, Paoli Carly J, Doad Gurinderpal, Panjabi Sumeet, De Marco Teresa
机构信息
Division of Pulmonary, Critical Care and Sleep Medicine Tufts Medical Center Boston Massachusetts USA.
Janssen Scientific Affairs, LLC Titusville New Jersey USA.
出版信息
Pulm Circ. 2024 Apr 15;14(2):e12326. doi: 10.1002/pul2.12326. eCollection 2024 Apr.
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.
导致肺动脉高压（PAH）治疗中断的相关因素信息有限。本研究分析了12902名新使用PAH药物的患者，以确定治疗中断的预测因素。由经认可的肺动脉高压中心进行治疗以及采用不同类别PAH药物的联合治疗导致治疗中断的可能性较小。
Zotero 插件